Japara Healthcare Ltd (ASX: JHC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Japara Healthcare Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Japara Healthcare Ltd (ASX: JHC)
Latest News

Share Market News
ASX 200 rises, Temple & Webster surges, Japara soars

Share Gainers
Why BlueScope, Japara, OZ Minerals, & Temple & Webster are storming higher

Healthcare Shares
Japara (ASX:JHC) share price soars 18% on takeover news

Broker Notes
Top brokers just upgraded these ASX shares to “buy”

Mergers & Acquisitions
Japara (ASX:JHC) share price shoots higher on second takeover offer

52-Week Highs
Why the Japara (ASX:JHC) share price just hit a 52-week high

Share Gainers
This beaten-up sector has some of the top performing ASX shares this year

Healthcare Shares
ASX aged care shares boosted after 2021 Federal Budget
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
26 Mar 2020 | $0.0200 | 50.00% | Interim | 30 Apr 2020 |
26 Sep 2019 | $0.0336 | 50.00% | Final | 30 Oct 2019 |
27 Mar 2019 | $0.0280 | 0.00% | Interim | 30 Apr 2019 |
27 Sep 2018 | $0.0376 | 50.00% | Final | 30 Oct 2018 |
27 Mar 2018 | $0.0400 | 65.00% | Interim | 30 Apr 2018 |
28 Sep 2017 | $0.0576 | 69.97% | Final | 30 Oct 2017 |
27 Mar 2017 | $0.0550 | 100.00% | Interim | 28 Apr 2017 |
27 Sep 2016 | $0.0575 | 100.00% | Final | 31 Oct 2016 |
07 Apr 2016 | $0.0575 | 100.00% | Interim | 16 May 2016 |
07 Oct 2015 | $0.0550 | 100.00% | 30 Oct 2015 | |
07 Apr 2015 | $0.0550 | 0.00% | 30 Apr 2015 |
JHC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Japara Healthcare Ltd
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
25 Oct 2021 | Christopher (Chris) Price | Buy | 1 | $2,016,000 |
Conversion of securities. Estimated valuation
|
25 Oct 2021 | Christopher (Chris) Price | Exercise | 1 | $2,016,000 |
Conversion of securities. Estimated valuation
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mrs Linda Bardo Nicholls | Non-Executive ChairmanNon-Executive Director | Mar 2014 |
Ms Nicholls AO is a senior executive and company director with more than 30 years' experience across Australia, New Zealand and the United States. In addition to her current Australian listed company directorships, she is Chairperson of Melbourne Health and a Member of the Museums Board of Victoria. Previously, she has held the position of Chairman at some of Australia's most wellregarded companies including Healthscope, Australia Post and Yarra Trams. Other current Australian listed company directorships: Medibank Private (appointed 31 March 2014), Inghams Group (appointed 7 October
2016) |
Mr David Paul Blight | Non-Executive Director | Mar 2014 |
Mr Blight is the co-founder and CEO of ARA Australia, the Australian business of the Singapore based ARA Group. ARA is an Asia Pacific real estate investment management firm with over $50 billion in funds under management. He is Chairman of IP Generation and IP Generation Fund Management and is a Non-Executive Director of Lifestyle Communities. His previous roles include Vice Chairman of ING Real Estate and Global Chairman and CEO of ING Real Estate Investment Management based in The Netherlands. He has also held senior executive positions with Armstrong Jones, Mirvac Group and APN Property Group. He has more than 30 years' experience in the real estate industry, across all major global markets and property sectors. Other current Australian listed company directorships: Lifestyle Communities (appointed 15 June 2018)
|
Dr Leanne Rowe | Non-Executive Director | Jul 2019 |
Ms Rowe AM is a Clinical Professor and Medical Practitioner with over 30 years of clinical experience in the public and private health systems across acute care, aged care, mental health and community health. She is Chairman of Nexus hospitals and in addition to her current Australian listed company directorships is a Non-Executive Director of the Medical Indemnity Protection Society and MIPS Insurance. Previously she was Chairman of the Royal Australian College of General Practitioners and a Non-Executive Director of I-MED Radiology Network, Medibank Private, GMHBA, Australian Health Management, Barwon Health and Beyond Blue. She is a former Deputy Chancellor of Monash University and has been awarded a Doctor of Laws (honoris causa) for her services. She has also received a Member of the Order of Australia for her services to medicine and is a Fellow of the Royal Australian College of General Practitioners and the Australian Institute of Company Directors. Other current Australian listed company directorships: Doctor Care Anywhere Group (appointed 17 September 2020), Australian Clinical Labs (appointed 28 April 2021)
|
Ms JoAnne Maree Stephenson | Non-Executive Director | Sep 2015 |
Ms Stephenson has over 25 years of extensive experience in financial services having been a partner with KPMG and has key strengths in finance, accounting, risk management and governance. She is Acting Chairman of Myer Holdings and a Non-Executive Director of Challenger. She is also Chair of the Major Transport Infrastructure Board (Victoria). Other current Australian listed company directorships: Challenger (appointed 8 October 2012), Myer Holdings (appointed 28 November 2016)
|
Mr Christopher (Chris) Price | Chief Executive OfficerManaging Director | Jul 2015 |
Mr Price has over 25 years of experience in the financial services, professional services and manufacturing sectors. Prior to joining the Company, he was Managing Director of former ASX listed professional services firm Crowe Horwath Australasia Limited, having previously served as its Chief Financial Officer for seven years. He is a member of Chartered Accountants Australia and New Zealand. He has not held any other directorships of listed companies in the last three years
|
Mr Bruce Craig Paterson | Company Secretary | Dec 2015 |
-
|
Anthony Rice | CFO and Chief investment Officer (CFO/CIO) |
-
|
|
Lindon Le Griffon | Chief Operations Officer (COO) |
-
|
|
Bruce Craig Paterson | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Citicorp Nominees Pty Limited | 31,156,876 | 11.66% |
Cs Third Nominees Pty Limited (HSBC Cust Nom Au Ltd 12 A/C) | 24,649,373 | 9.22% |
HSBC Custody Nominees (Australia) Limited | 23,486,248 | 8.79% |
The Trust Company (Australia) Limited (A/C 4) | 19,361,813 | 7.24% |
Ashens Properties Pty Ltd (Sudholz Family Discretionary Trust A/C) | 15,127,179 | 5.66% |
Moelis Australia Asset Management Ltd (Moelis Aus Partners A/C) | 14,984,821 | 5.61% |
J P Morgan Nominees Australia Pty Limited | 14,875,902 | 5.57% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 8,283,401 | 3.10% |
Sudsie Pty Ltd | 5,858,333 | 2.19% |
National Nominees Limited | 5,382,305 | 2.01% |
Cs Fourth Nominees Pty Limited (HSBC Cust Nom Au Ltd 11 A/C) | 3,732,837 | 1.40% |
Brispot Nominees Pty Ltd (House Head Nominee A/C) | 3,325,381 | 1.24% |
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd (Drp A/C) | 3,050,473 | 1.14% |
Neweconomy Com Au Nominees Pty Limited (900 Account) | 2,738,549 | 1.02% |
Cs Third Nominees Pty Limited (HSBC Cust Nom Au Ltd 13 A/C) | 2,565,850 | 0.96% |
Manken (Manken Family Super A/C) | 2,310,000 | 0.86% |
BNP Paribas Noms Pty Ltd (Drp) | 2,232,590 | 0.84% |
Morgan Stanley Australia Securities (Nominee) Pty Limited (No 1 Account) | 1,842,439 | 0.69% |
Bundarra Trading Company Pty Ltd (Thomas Emery Kennedy A/C) | 1,700,000 | 0.64% |
Sep Super Pty Ltd (Sep Super Fund A/C) | 1,311,480 | 0.49% |